Evidence for astrocytosis in ALS demonstrated by 11C(L)-deprenyl-D2 PET
2007 (English)In: Journal of the Neurological Sciences, ISSN 0022-510X, E-ISSN 1878-5883, Vol. 255, no 1-2, 17-22 p.Article in journal (Refereed) Published
Objective: To use deuterium-substituted [11C](l)-deprenyl PET to depict astrocytosis in vivo in patients with amyotrophic lateral sclerosis (ALS). Background: In human brain, the enzyme MAO-B is primarily located in astrocytes. l-deprenyl binds to MAO-B and autoradiography with 3H-l-deprenyl has been used to map astrocytosis in vitro. Motor neuron loss in ALS is accompanied by astrocytosis and astrocytes may play an active role in the neurodegenerative process. Deuterium-substituted [11C](l)-deprenyl PET provides an opportunity to localize astrocytosis in vivo in the brain of patients with ALS. Methods: Deuterium-substituted [11C](l)-deprenyl PET was performed in seven patients with ALS and seven healthy control subjects. Results: Increased uptake rate of [11C](l)-deprenyl was demonstrated in ALS in pons and white matter. Conclusion: This study provides evidence that astrocytosis may be detected in vivo in ALS by the use of deuterium-substituted [11C](l)-deprenyl PET though further studies are needed to determine whether deuterium-substituted [11C](l)-deprenyl binding tracks disease progression and reflects astrocytosis.
Place, publisher, year, edition, pages
2007. Vol. 255, no 1-2, 17-22 p.
Amyotrophic lateral sclerosis, ALS, Motor neuron disease, Astrocytosis, PET, MAO-B, Deprenyl
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-10812DOI: 10.1016/j.jns.2007.01.057ISI: 000245849000003PubMedID: 17346749OAI: oai:DiVA.org:uu-10812DiVA: diva2:38580